Back to Journals » Adolescent Health, Medicine and Therapeutics » Volume 4

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics

Authors Larson KB, King JR, Acosta EP

Received 29 May 2013

Accepted for publication 4 July 2013

Published 27 August 2013 Volume 2013:4 Pages 79—87

DOI https://doi.org/10.2147/AHMT.S29462

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Kajal B Larson, Jennifer R King, Edward P Acosta

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract: Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can be used in treatment-naïve and -experienced patients, as well as for the treatment of multidrug-resistant infection. Raltegravir exists in two formulations: a film-coated tablet administered orally at 400 mg twice daily, and a chewable tablet administered orally at 300 mg twice daily. In 2011, raltegravir was also approved for the treatment of children and adolescents, ages 2–18 years. For adolescents (ages 12–18 years), the recommended dose is 400 mg twice daily (film-coated tablet). If children (ages 6–12 years) weigh at least 25 kg, the film-coated tablet is recommended at 400 mg twice daily. Otherwise, patients receive the chewable tablet according to weight-based dosing at approximately 6 mg/kg/dose. Studies are ongoing for children ages 4 weeks to 2 years, and preliminary efficacy and safety data are promising. This article reviews current studies on the efficacy, safety, and pharmacokinetics of raltegravir in the pediatric population and the challenges of treating HIV in children and adolescents.

Keywords: raltegravir, pediatrics, pharmacokinetics, safety, efficacy

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.